GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Total Receivables

Radiopharm Theranostics (ASX:RAD) Total Receivables : A$4.41 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Total Receivables?

Radiopharm Theranostics's Total Receivables for the quarter that ended in Dec. 2023 was A$4.41 Mil.


Radiopharm Theranostics Total Receivables Historical Data

The historical data trend for Radiopharm Theranostics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Total Receivables Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Total Receivables
0.06 4.47 0.99

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial 0.06 4.08 4.47 4.41 0.99

Radiopharm Theranostics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Radiopharm Theranostics Total Receivables Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Radiopharm Theranostics Headlines

No Headlines